Our Head of Research and Development, Dr Ingrid Rauter, talks in the Swiss magazine Sprechstunde Dr Stutz about customised tumour treatment and the development of a promising method to reduce the recurrence of kidney cancer.
Link: Neuer Impfstoff gegen Nierenkrebs - Sprechstunde Doktor Stutz
